Loxo Oncology Inc

Loxo Oncology — Technical Presentation (November 2015)

19 slides from Loxo Oncology's technical presentation, Nov 9, 2015

  1. Slide 1: Disclosures

    Disclosures Author Disclosures David S. Hong Travel expenses supported by Loxo Oncology Marcia S. Brose None Robert C. Doebele Research grant from Loxo Oncology Alice T. Shaw None Afshin Dowlati None Todd M. Bauer None Anna F. Farago None Adriana Estrada-Bernal Research grant from Loxo Oncology Anh

  2. Slide 2: TRK Fusions are Oncogenic and Signal Through Canonical Downstream Pathways

    TRK Fusions are Oncogenic and Signal Through Canonical Downstream Pathways Normal TRK Proteins Family of neurotrophin receptors TrkA (NTRK1) Pain, thermoregulation TrkB (NTRK2) Movement, memory, mood, appetite, body weight TrkC (NTRK3) Proprioception TRK Fusions Ligand binding domain replaced by 5’

  3. Slide 3: TRK Fusions Found in Diverse Cancer Histologies

    TRK Fusions Found in Diverse Cancer Histologies 4 TRK Fusion Frequency <5% 5–25% >75% CNS Astrocytoma Brain low-grade glioma Glioblastoma GI Colorectal cancer Cholangiocarcinoma Pancreatic cancer Head and neck Squamous cell carcinoma Lung Adenocarcinoma Large cell neuroendocrine Other Acute myeloid

  4. Slide 4: LOXO-101: A Rationally Designed Selective TRK Inhibitor

    LOXO-101: A Rationally Designed Selective TRK Inhibitor 5 Chartier M, Chénard T, Barker J, Najmanovich R. (2013) Kinome Render: a stand-alone and web-accessible tool to annotate the human protein kinome tree. PeerJ 1:e126 TRK TRK LOXO-101 rationally designed High potency against TRKA, TRKB, TRKC and

  5. Slide 5: LOXO-101 In Vitro and In Vivo Activity

    In Vivo: Tumor Regressions in TRK Fusion Xenografts LOXO-101 In Vitro and In Vivo Activity 6 In Vitro: Potency in TRK Fusion Cell Models; Spares Unselected Cell Models Courtesy of the Doebele lab. Doebele et al. Cancer Discov. 2015 Oct;5(10):1049-57 0 2 4 6 8 10 12 0 200 400 600 Time (Days) T u m o

  6. Slide 6: LOXO-101 Phase 1 Study Design

    LOXO-101 Phase 1 Study Design Ongoing dose escalation study Advanced or metastatic solid tumors ECOG 0/1, normal organ function QD or BID oral continuous dosing, 28-day cycles Outcome measures Safety and tolerability Pharmacokinetics measured at cycle 1, days 1 and 8 Efficacy assessments conducted e

  7. Slide 7: Baseline Characteristics

    Baseline Characteristics characteristics Subjects (N= 30) Median age (range), years 55.0 (28 – 76) Sex Male / Female 18 (60%) / 12 (40%) Race White / Black / Other 20 (67%) / 6 (20%) / 4 (13%) Tumor Type Head and Neck 6 (20%) Lung 5 (17%) Pancreatic 3 (10%) Breast 2 (7%) Colorectal 2 (7%) Sarcoma 2

  8. Slide 8: Baseline Characteristics

    Baseline Characteristics CHARACTERISTICS. Median age (renge), years ‘Sex ‘SUBJECTS (N= 30) 55.0 (28-76) 18 (60%) / 12 (40%) ace 20 (67%) / 6 (20%) / 4 (13%) “Tumor Type ECOG Status 12 (40%) 718 (60%) Prior systemie anticancer therapy, a (6). = 29 (97%) Median number of regimens (ange) 3 (0-41) ‘TRK-

  9. Slide 9: Linear PK profile following oral administration shows high plasma exposure

    Linear PK profile following oral administration shows high plasma exposure and no accumulation 100 mg BID: IC90 target coverage, favorable safety, and early efficacy LOXO-101 Exposure 10 The horizontal line representing TRKA IC90 refers to the total plasma concentration of LOXO-101 that is associate

  10. Slide 10: LOXO-101 Phase 1 Interim Treatment-Emergent AEs

    LOXO-101 Phase 1 Interim Treatment-Emergent AEs, Regardless of Attribution to Study Drug Dose 100 mg BID (n=11) Total (n=30) Adverse Events (AEs)* Gr 3/4 All Gr Gr 3/4 All Gr n (%) n (%) n (%) n (%) Fatigue 0 2 (18%) 1 (3%) 10 (33%) Dizziness 0 5 (45%) 0 9 (30%) Anemia 0 2 (18%) 2 (7%) 6 (20%) Nause

  11. Slide 11: LOXO-101 Enrollment and Summary of Efficacy

    LOXO-101 Enrollment and Summary of Efficacy 6 patients with TRK fusions enrolled; all currently on study Soft tissue sarcoma (LMNA-NTRK1) GIST (ETV6-NTRK3) Mammary analogue secretory carcinoma (ETV6-NTRK3) Thyroid carcinoma (ETV6-NTRK3) Mammary analogue secretory carcinoma (ETV6-NTRK3) NSCLC (TPR-NT

  12. Slide 12: LOXO-101 Enrollment and Summary of Efficacy

    LOXO-101 Enrollment and Summary of Efficacy * 6 patients with TRK fusions enrolled; all currently on study + Soft tissue sarcoma (LMNA-NTRK1) 2 Sans) k + Mammary analogue secretory carcinoma (ETV6-NTRK3) * Thyroid carcinoma (ETV6-NTRK3) * Mammary analogue secretory carcinoma (ETV6-NTRK3) k + NSCLC (

  13. Slide 13: Patient #1: LMNA-NTRK1 fusion soft tissue sarcoma

    Patient #1: LMNA-NTRK1 fusion soft tissue sarcoma 42 yo female with undifferentiated sarcoma progressed through epirubicin, ifosfamide, sorafenib, and doxorubicin 100mg BID Rapid resolution of dyspnea and hypoxemia Confirmed partial response Currently on study; 8+ months Study baseline Study cycle 9

  14. Slide 14: Patient #2: ETV6-NTRK3 fusion GIST

    Patient #2: ETV6-NTRK3 fusion GIST 55 yo male with GIST progressed through imatinib, sunitinib, sorafenib, nilotinib, and regorafenib 150mg BID Confirmed partial response Currently on study; 4+ months 15 CT PET Study baseline Study cycle 5 day 1 Study baseline Study cycle 3 day 1

  15. Slide 15: Patient #3: ETV6-NTRK3 fusion mammary analogue secretory carcinoma

    Study baseline Study cycle 3 day 1 Patient #3: ETV6-NTRK3 fusion mammary analogue secretory carcinoma of the salivary gland (MASC) 33 yo male progressed through docetaxel, carboplatin and 5FU 100mg BID Partial response Currently on study; 3+ months 16

  16. Slide 16: Conclusions

    Conclusions LOXO-101 is a purpose-built, oral, selective and potent TRK inhibitor with tumor regression in TRK-fusion preclinical xenograft models PK analyses demonstrate very high Cmax (mean levels >IC90) and linear PK with no significant drug accumulation LOXO-101 is well tolerated, with most comm

  17. Slide 17: LOXO-101 Phase 2 Adult Basket Trial

    LOXO-101 Phase 2 Adult Basket Trial First Patient Enrolled, October 2015 Adult solid tumors, including CNS tumors, with TRK fusion based on local or pre-existing testing Dose: 100mg BID Primary endpoint: Best overall response by RECIST or RANO Global study (20-30 sites) to enroll up to 18 patients p

  18. Slide 18: Acknowledgements

    Acknowledgements LOXO-101 patients and their families and caregivers Co-investigators and study support staffs This trial sponsored and supported by Loxo Oncology 19

  19. Slide 19: Acknowledgements

    Acknowledgements * LOXO-101 patients and their families and caregivers * Co-investigators and study support staffs * This trial sponsored and supported by Loxo Oncology

Loxo Oncology — Technical Presentation (November 2015) on 6ix